Globus Medical Operating Margin 2010-2022 | GMED

Current and historical operating margin for Globus Medical (GMED) over the last 10 years. The current operating profit margin for Globus Medical as of September 30, 2022 is 20.29%.
Globus Medical Operating Margin Historical Data
Date TTM Revenue TTM Operating Income Operating Margin
2022-09-30 $1.00B $0.19B 19.22%
2022-06-30 $0.98B $0.19B 18.97%
2022-03-31 $0.96B $0.16B 16.94%
2021-12-31 $0.96B $0.17B 17.95%
2021-09-30 $0.94B $0.21B 22.64%
2021-06-30 $0.93B $0.21B 22.65%
2021-03-31 $0.83B $0.14B 16.73%
2020-12-31 $0.79B $0.11B 14.07%
2020-09-30 $0.77B $0.10B 13.28%
2020-06-30 $0.75B $0.09B 12.57%
2020-03-31 $0.79B $0.16B 20.53%
2019-12-31 $0.79B $0.17B 21.88%
2019-09-30 $0.77B $0.17B 21.43%
2019-06-30 $0.74B $0.16B 21.67%
2019-03-31 $0.72B $0.16B 22.19%
2018-12-31 $0.71B $0.17B 23.74%
2018-09-30 $0.69B $0.17B 25.14%
2018-06-30 $0.68B $0.17B 25.48%
2018-03-31 $0.65B $0.17B 25.54%
2017-12-31 $0.64B $0.16B 25.31%
2017-09-30 $0.61B $0.15B 24.35%
2017-06-30 $0.60B $0.15B 25.34%
2017-03-31 $0.58B $0.15B 26.16%
2016-12-31 $0.56B $0.16B 27.48%
2016-09-30 $0.56B $0.18B 31.53%
2016-06-30 $0.56B $0.18B 32.01%
2016-03-31 $0.55B $0.18B 32.01%
2015-12-31 $0.55B $0.17B 31.68%
2015-09-30 $0.53B $0.16B 29.51%
2015-06-30 $0.51B $0.15B 29.43%
2015-03-31 $0.49B $0.15B 29.61%
2014-12-31 $0.48B $0.14B 29.26%
2014-09-30 $0.46B $0.13B 28.42%
2014-06-30 $0.45B $0.13B 28.00%
2014-03-31 $0.44B $0.11B 23.70%
2013-12-31 $0.43B $0.10B 23.50%
2013-09-30 $0.42B $0.10B 23.57%
2013-06-30 $0.41B $0.10B 23.53%
2013-03-31 $0.40B $0.12B 29.22%
2012-12-31 $0.39B $0.12B 29.72%
2012-09-30 $0.37B $0.11B 29.41%
2012-06-30 $0.36B $0.11B 30.30%
2012-03-31 $0.35B $0.10B 29.60%
2011-12-31 $0.33B $0.10B 29.61%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $7.506B $0.958B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $226.442B 23.68
Edwards Lifesciences (EW) United States $48.354B 33.28
Alcon (ALC) Switzerland $36.722B 31.62
STERIS (STE) Ireland $20.456B 25.46
Teleflex (TFX) United States $11.305B 18.34
Fresenius Medical Care AG KGaA (FMS) Germany $10.584B 10.62
Penumbra (PEN) United States $9.289B 2223.46
Integer Holdings (ITGR) United States $2.380B 19.11
Glaukos (GKOS) United States $2.298B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.402B 19.97
Paragon 28 (FNA) United States $1.303B 0.00
Nevro (NVRO) United States $1.291B 0.00
Artivion (AORT) United States $0.505B 0.00